UNSPSC 51142572: Selegiline hydrochloride

This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6W731X367Q, chemically known as (-)-(r)-n,alpha-dimethyl-n-2-propynylphenethylamine monohydrochloride but more generally known as selegiline hydrochloride, which bears US NIH Compound Identifier 26758. European Medicines Agency schedules Selegiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04347MIG.

Most nations, for tariff and trade purposes, schedule selegiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, SELEGILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Selegiline hydrochloride bears US NLM identifiers UMLS ID C0700467 and NCI Concept Code C47714. SMILES: C[C@H](CC1CCCCC1)N(C)CC#C.CL.

UNSPSC 51142572 Selegiline hydrochloride is a Commodity code that state and local governments use to classify pharmaceutical procurement, though recent activity shows the code tagged to broader generic and OTC medication sourcing rather than selegiline alone. State and local buyers under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope of work covers supply of generic pharmaceuticals and OTC products through authorized wholesaler networks, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and specific insurance coverages including commercial general liability and professional liability. Contracts typically run two years with optional renewals and are awarded on a fixed-fee or net-pricing basis with administrative fees; vendors must fulfill quarterly or ongoing deliveries to designated state and local facilities and comply with E-Verify and drug-free workplace requirements.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 (note: the date appears inconsistent in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with responses due the same date. Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, with a March 26, 2026 response deadline; the RFP requires vendors to work through three authorized wholesalers and evaluates proposals on price competitiveness (75 percent), fixed pricing, EDI capability, and cGMP/DSCSA compliance. The three opportunities reflect a mix of direct county procurement, state exploratory market research, and cooperative multi-jurisdictional purchasing mechanisms.